vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and XBP Global Holdings, Inc. (XBP). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $152.4M, roughly 1.3× XBP Global Holdings, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -34.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AXSM vs XBP — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $152.4M |
| Net Profit | — | $-305.8M |
| Gross Margin | — | 21.7% |
| Operating Margin | -33.1% | -191.7% |
| Net Margin | — | -200.7% |
| Revenue YoY | 57.4% | -34.7% |
| Net Profit YoY | — | -980.1% |
| EPS (diluted) | — | $-2.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | — | ||
| Q3 25 | $171.0M | $152.4M | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | $233.4M | ||
| Q2 24 | $87.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-305.8M | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-28.3M | ||
| Q2 24 | $-79.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 21.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | — |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | -191.7% | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | 0.9% | ||
| Q2 24 | -89.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -200.7% | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -12.1% | ||
| Q2 24 | -91.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | $-2.60 | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | $-0.09 | ||
| Q2 24 | $-1.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $34.5M |
| Total DebtLower is stronger | $70.0M | $381.5M |
| Stockholders' EquityBook value | — | $130.5M |
| Total Assets | $713.6M | $947.9M |
| Debt / EquityLower = less leverage | — | 2.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | $34.5M | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | $7.8M | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $381.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $31.5M | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | — | ||
| Q3 25 | $73.7M | $130.5M | ||
| Q2 25 | $73.1M | — | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | $-1.3B | ||
| Q2 24 | $102.9M | — |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | — | ||
| Q3 25 | $669.3M | $947.9M | ||
| Q2 25 | $639.8M | — | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | $99.6M | ||
| Q2 24 | $548.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.92× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $13.9M |
| Free Cash FlowOCF − Capex | — | $10.5M |
| FCF MarginFCF / Revenue | — | 6.9% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $1.0M | $13.9M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.4M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.6M | $-1.5M | ||
| Q2 24 | $-30.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | $10.5M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | $-6.1M | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | 6.9% | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | -2.6% | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
XBP
| Related And Non Related Party | $136.5M | 90% |
| Technology | $8.2M | 5% |
| Other | $5.7M | 4% |
| Deferred Revenue As Of July312025 | $1.9M | 1% |
